ClinicalTrials.gg
RecruitingNCT06614309Updated Jun 5, 2026

Non-invasive Treatment for Long COVID (Post COVID-19 Condition) Brain Fog

An interventional study of Acute Placebo Visit and Acute Progressive Carbon Dioxide in Long COVID, sponsored by Mayo Clinic. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-05.

Sponsored by Mayo Clinic · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2024; still recruiting 2 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 195 studies in Post-Acute COVID-19 Syndrome with a site in United States — 63 open to participants now, 85 under way, 7 of them phase 3. Post-Acute COVID-19 Syndrome · United States.

Planned enrollment
88th of 156
45 · median 53
Started
2024
with 42 others
No phase
78 of 195
23 open now
Primary completion
2026-12
later than 31 of 84 live
Registered
151st of 195
by date
Lead sponsor
4 of 195
Mayo Clinic

Among the 195 studies in Post-Acute COVID-19 Syndrome with a site in United States, this one is the 88th largest by planned enrollment of the 156 interventional ones that give a count, is one of 43 that started in 2024, is one of 78 with no phase, reaches primary completion later than 31 of the 84 other live ones, and was the 151st registered.

Post-Acute COVID-19 Syndrome

606 studies on the registry are indexed under Post-Acute COVID-19 Syndrome; 201 are open to participants now.

Browse Post-Acute COVID-19 Syndrome studies →

Open to participants now

63 of the 195 studies in Post-Acute COVID-19 Syndrome with a site in United States are open now. Recruiting first, the newest first:

58 more — sign in →

All 63 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 144 Post-Acute COVID-19 Syndrome studies recruiting now, 69 (48%) set no upper age limit and 53 (37%) stop at 75 or younger; 15 take children under 18; 39 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 195 studies in Post-Acute COVID-19 Syndrome with a site in United States, or all of them as a file.
02

Study summary

This study aims to assess the effects of both acute and chronic exposures to hypoxia and hypercapnia in patients with Long COVID syndrome.

03

Conditions studied

  • Long COVID

Keywords

  • brain fog
  • brain blood flow
  • heart rate variability
  • fatigue
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • English speaking
  • Diagnosis of Long COVID

Exclusion criteria

Exclusion criteria:

  • Any history of:

    • Coronary artery dissection or aortic dissection
    • Neurological disease (e.g. dementia, Alzheimer's disease, or other brain-related disease)
    • Cerebrovascular disease or stroke
    • Aneurysm
  • If currently has:

    • Moderate-severe
    • Uncontrolled moderate-severe asthma
    • Moderate-severe bronchiectasis
    • Moderate-severe interstitial lung disease, requiring the use of supplemental oxygen
    • A necessity to use supplemental oxygen, for any reason
    • New or worsening symptoms (decompensation) of heart failure
    • Right heart disease due to chronic pulmonary disease/sleep apnea
    • Uncontrolled myocardial ischemia or angina
    • Uncontrolled heart arrhythmias
    • Heart or lung infection (e.g. myocarditis or pericarditis)
    • Left main coronary artery stenosis
    • Moderate-severe aortic stenosis
    • Pulmonary embolism, pulmonary infarction, or other blood clots
    • Severe respiratory disease
    • Chronic kidney disease
    • Chronic liver disease
  • Females of will complete a urine pregnancy test at their baseline visit to rule out pregnancy
  • >40
  • Study staff unable to obtain adequate signal for cerebral blood flow
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
45 participants (estimated)

Study arms

  • Experimental
    Acute exposure: Placebo, Progressive Carbon Dioxide, Intermittent Hypoxia

    Study group will receive the three interventions in this order: Placebo, Progressive Carbon Dioxide, then Intermittent Hypoxia

    Other: Acute Placebo Visit · Other: Acute Progressive Carbon Dioxide · Other: Acute Intermittent Hypoxia

  • Experimental
    Acute exposure: Placebo, Intermittent Hypoxia, Progressive Carbon Dioxide

    Study group will receive the three interventions in this order: Placebo, Intermittent Hypoxia, Progressive Carbon Dioxide

    Other: Acute Placebo Visit · Other: Acute Progressive Carbon Dioxide · Other: Acute Intermittent Hypoxia

  • Experimental
    Acute exposure: Intermittent Hypoxia, Placebo, Progressive Carbon Dioxide

    Study group will receive the three interventions in this order: Intermittent Hypoxia, Placebo, Progressive Carbon Dioxide

    Other: Acute Placebo Visit · Other: Acute Progressive Carbon Dioxide · Other: Acute Intermittent Hypoxia

  • Experimental
    Acute exposure: Intermittent Hypoxia, Progressive Carbon Dioxide, Placebo

    Study group will receive the three interventions in this order: Intermittent Hypoxia, Progressive Carbon Dioxide, Placebo

    Other: Acute Placebo Visit · Other: Acute Progressive Carbon Dioxide · Other: Acute Intermittent Hypoxia

  • Experimental
    Acute exposure: Progressive Carbon Dioxide, Placebo, Intermittent Hypoxia

    Study group will receive the three interventions in this order: Progressive Carbon Dioxide, Placebo, Intermittent Hypoxia

    Other: Acute Placebo Visit · Other: Acute Progressive Carbon Dioxide · Other: Acute Intermittent Hypoxia

  • Experimental
    Acute exposure: Progressive Carbon Dioxide, Intermittent Hypoxia, Placebo

    Study group will receive the three interventions in this order: Progressive Carbon Dioxide, Intermittent Hypoxia, Placebo

    Other: Acute Placebo Visit · Other: Acute Progressive Carbon Dioxide · Other: Acute Intermittent Hypoxia

  • Placebo comparator
    Placebo Group

    Study group will complete 6 simulated cycles of 5 minutes breathing 21% oxygen from a douglas bag and 5 minutes breathing room air (60 minutes) for every visit during the 14 days intervention period. Subjects will then return within 7 days of their final training visit to repeat baseline testing

    Other: Training: Placebo Control

  • Experimental
    Training Group

    Training Study group will be complete 6 cycles of either progressive CO2 ramp protocol or the intermittent hypoxia protocol for 60 minutes for every visit during the 14 days. Subjects will then return within 7 days of their final training visit to repeat baseline testing

    Other: Training: Progressive Carbon Dioxide Ramping · Other: Training: Intermittent Hypoxic Exposure

Interventions

  • OtherAcute Placebo Visit

    The placebo visit will include 6 simulated cycles of 5 minutes breathing 21% oxygen from a douglas bag and 5 minutes breathing room air.

  • OtherAcute Progressive Carbon Dioxide

    The progressive carbon dioxide visit will include a 60-minute progressive ramp which includes 6 cycles of progressive CO2 ramping starting at 0% and progressing up to 10% within 5 minutes immediately followed with 5 minutes of room air breathing in between cycles.

  • OtherAcute Intermittent Hypoxia

    The intermittent hypoxia exposure visit will include 6 cycles breathing 8-12% oxygen (O2) for 5 minutes with a target pulse oximeter saturation of 86-90%, followed by 5 minutes of breathing room air.

  • OtherTraining: Progressive Carbon Dioxide Ramping

    Intervention will consist of 6 to 10 study visits (3-5 sessions/week) to be completed within 14 days. Subjects will will be given the progressive CO2 ramp protocol of 60-minute sessions, which will include 6 cycles of progressive CO2 ramping starting at 0% and progressing up to 10% within 5 minutes immediately followed with 5 minutes of room air breathing in between cycles, for every visit during the 14 days.

  • OtherTraining: Intermittent Hypoxic Exposure

    Intervention will consist of 6 to 10 study visits (3-5 sessions/week) to be completed within 14 days. Subjects will will be given the intermittent hypoxia exposure protocol of 60-minute sessions, which will include 6 cycles breathing 8-12% oxygen (O2) for 5 minutes with a target pulse oximeter saturation of 86-90%, followed by 5 minutes of breathing room air for every visit during the 14 days.

  • OtherTraining: Placebo Control

    Intervention will consist of 6 to 10 study visits (3-5 sessions/week) to be completed within 14 days. Subjects will complete 6 simulated cycles of 5 minutes breathing 21% oxygen from a douglas bag and 5 minutes breathing room air (60 minutes) for every visit during the 14 days.

06

What researchers measure

Primary outcomes

  1. Change in cerebral blood flow

    The intracranial middle cerebral arteries will be obtained (MCAv) will be imaged with a linear probe and duplex ultrasound system to simultaneously measure CBFv by pulse wave doppler (peak and mean flow)

    Time frame: Baseline, post-acute exposure and 14 days post training

  2. Change in heart rate variability

    Short- term HRV analysis of a 3-lead ECG recording (5 minute recording) will evaluate both time-domain parameters (mean heart rate, standard deviation of normal-to-normal (NN) intervals (SDNN) and root mean square of successive differences between NN intervals rMSSD) and frequency-domain parameters (total power, high frequency (HF) and low frequency (LF) and LF/HF ratio).

    Time frame: Baseline, post-acute exposure and 14 days post training

  3. Change in brain fog scale

    Questionnaire assessing of how much brain fog is affecting daily abilities

    Time frame: Baseline, post-acute exposure and 14 days post training

Secondary outcomes

  1. Change in fatigue functional assessment of chronic illness therapy-fatigue scale

    Fatigue functional assessment of chronic illness therapy-fatigue scale (FACIT-Fatigue): assessment of how much fatigue is affecting daily abilities. Scores range from 0-52 for the FACIT with a higher score indicating higher levels of fatigue experienced.

    Time frame: Baseline, post-acute exposure and 14 days post training

  2. Change in short form health survey (SF-36)

    The Short Form (SF-36) Health Survey is a 36-item, participant-reported survey that measures patient health and disability. Possible scores range from 0 to 100, with 0 indicating maximum disability, and 100 indicating no disability.

    Time frame: Baseline, post-acute exposure and 14 days post training

  3. Change in Trail making test

    Trail making test: Consists of two parts. For part one, the subject will be presented with 25 numbered dots. The goal is to connect all 25 dots in numerical order quickly and accurately. The second part consists of 25 dots on the screen labelled with numbers and letters. The subject will then click the dots in sequential order by number followed by letter. For example, 1-A-2-B-3-C…, in the shortest amount of time possible while maintaining accuracy.

    Time frame: Baseline, post-acute exposure and 14 days post training

  4. Change in rapid cognitive assessment tool (RCAT) score

    The premise is to click spawning targets quickly and accurately. The assessment lasts one minute during which the game will add or reduce intensity based on real time performance. It is used to interpret psychological and psychomotor functions including hand-eye coordination, speed, response time, spatial awareness, situational awareness, and decision-making. Test takes one minute and score is calculate based on number of correct clicks.

    Time frame: Baseline, post-acute exposure and 14 days post training

  5. Change in Task switching test performance

    Task switching test will evaluate the individual's ability to switch between different tasks or operations. Participants are presented with a number between 1 and 9. The number will appear in one of two colors: purple or yellow. If the number is purple, the participant will answer with yes or no if the number is even. If yellow, the participants will answer with yes or no if the number is less than 5. Participants will see 40 numbers and their performance will be scored based on response time and accuracy.

    Time frame: Baseline, post-acute exposure and 14 days post training

  6. Change in Rey Auditory Verbal Learning Test (AVLT) recall

    Rey Auditory Verbal Learning Test (AVLT) will assess short term auditory recall. Subjects are read a list of 15 words and asked to repeat as many words as possible that they can remember back to the test administrator. They repeat this 5 times, then read a new list of 15 words to repeat back one time before returning to recall the first list of words.

    Time frame: Baseline, post-acute exposure and 14 days post training

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Dec 2026, 27 months after the start.

Of 232 non-industry interventional studies with no phase under Post-Acute COVID-19 Syndrome, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 28. This study's planned 27 months is above that.

Counting every sponsor, half of 243 studies reached it within 16 months; a quarter within 7 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2024
First posted
Sep 26, 2024
StartActual
Sep 24, 2024
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Jun 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06614309
Lead sponsor
Mayo Clinic
Responsible party
Courtney M. Wheatley (Principal Investigator, Mayo Clinic) — Principal investigator
First posted
Sep 26, 2024
Start date
Sep 24, 2024
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Jun 5, 2026

Study contacts

Jordan Parks
Contact
parks.jordan@mayo.edu
480-301-6616
Courtney Wheatley-Guy
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion